2/16-OHE1 Cancer Research Results

2/16-OHE1, 2-OHE1/16α-OHE1 Ratio/2-Hydroxyestrone to 16α-Hydroxyestrone Ratio: Click to Expand ⟱
Source:
Type:

2-OHE1/16α-OHE1 Ratio - 2-Hydroxyestrone to 16α-Hydroxyestrone Ratio

Abbreviation: 2/16-OHE1 ratio, 2-OHE1/16α-OHE1, EMR

Type: Estrogen metabolism biomarker / metabolite ratio

Function: Represents the relative metabolism of estrone through the 2-hydroxylation versus 16α-hydroxylation pathways. 2-Hydroxyestrone has relatively weak estrogenic activity, whereas 16α-hydroxyestrone has greater estrogenic and potentially genotoxic/proliferative activity.

Cancer: ↓ A lower 2-OHE1/16α-OHE1 ratio has historically been proposed to represent a less favorable estrogen-metabolism profile and potentially greater breast-cancer risk, while an increased ratio has been considered potentially favorable. However, prospective studies and systematic reviews have found inconsistent associations, and the ratio is not considered a validated predictor of breast-cancer risk.

Direction: ↑ Traditionally considered favorable, but clinical significance remains uncertain.
Scientific Papers found: Click to Expand⟱
8830- DIM,  Tam,    A randomized, placebo-controlled trial of diindolylmethane for breast cancer biomarker modulation in patients taking tamoxifen
- Trial, BC, NA
Dose?, 2/16-OHE1↓, SHBG↑,
8831- DIM,    3,3′-Diindolylmethane Exhibits Significant Metabolism after Oral Dosing in Humans
- Human, Nor, NA
*chemoPv↑, *Dose↝, *Half-Life?, *BioAv↝, NA↑, CYP1A2↑, 2/16-OHE1↑, AR↝, BioAv↑,
8832- DIM,    Phase Ib placebo-controlled, tissue biomarker trial of diindolylmethane (BR-DIMNG) in patients with prostate cancer who are undergoing prostatectomy
- Trial, Pca, NA
Dose?, *toxicity↓, BioAv↑, 2/16-OHE1↝, eff↝,
7601- I3C,    Prevention and treatment of cancer with indole-3-carbinol
- Review, BC, NA
Estro↝, 2/16-OHE1↑, chemoPv↑,
7602- I3C,    Dose-ranging study of indole-3-carbinol for breast cancer prevention
- Trial, BC, NA
toxicity↓, Dose↝, 2/16-OHE1↑, chemoPv↑,
7604- I3C,    Multifunctional aspects of the action of indole-3-carbinol as an antitumor agent
- in-vitro, Var, NA
2/16-OHE1↑, CYP1B1↓, 4-OHE1↓, Apoptosis↑, cycD1/CCND1↓, TumCCA↑, AntiTum↑,
7606- I3C,    Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol
- Human, Nor, NA
P450↝, 2/16-OHE1↑,
7611- I3C,    Long-term responses of women to indole-3-carbinol or a high fiber diet
- Trial, Nor, NA
*Dose↝, *2/16-OHE1↑,

Showing Research Papers: 1 to 8 of 8

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↓, 1,   2/16-OHE1↑, 5,   2/16-OHE1↝, 1,   4-OHE1↓, 1,   AR↝, 1,   Estro↝, 1,   SHBG↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 2,   CYP1A2↑, 1,   CYP1B1↓, 1,   Dose?, 2,   Dose↝, 1,   eff↝, 1,   P450↝, 1,  

Clinical Biomarkers(tgid=22) ⓘ

AR↝, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiTum↑, 1,   chemoPv↑, 2,   toxicity↓, 1,  
Total Targets: 22

Pathway results for Effect on Normal Cells:


Hormonal & Nuclear Receptors(tgid=20) ⓘ

2/16-OHE1↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   Dose↝, 2,   Half-Life?, 1,  

Functional Outcomes(tgid=23) ⓘ

chemoPv↑, 1,   toxicity↓, 1,  
Total Targets: 6

Scientific Paper Hit Count for: 2/16-OHE1, 2-OHE1/16α-OHE1 Ratio/2-Hydroxyestrone to 16α-Hydroxyestrone Ratio
5 Indole-3-carbinol
3 Diindolylmethane
1 tamoxifen
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:1669  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page